Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 4 Stomach Neoplasms 3 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Hematologic Neoplasms 1 HER2-positive Breast Cancer 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Metastatic 1

Interventions

pembrolizumab 157 Gemcitabine 140 Capecitabine 123 Paclitaxel 121 Fluorouracil 117 Oxaliplatin 110 Bevacizumab 106 Nivolumab 99 Docetaxel 98 Leucovorin 97 Cisplatin 90 Radiosurgery 88 Irinotecan 88 Carboplatin 86 Cyclophosphamide 72 Cetuximab 72 Magnetic Resonance Spectroscopy 68 Specimen Handling 60 Radiotherapy 60 Trastuzumab 59 Biopsy 59 Ipilimumab 53 Drug Therapy 51 Everolimus 48 Pemetrexed 46 Albumin-Bound Paclitaxel 45 130-nm albumin-bound paclitaxel 44 Doxorubicin 42 Fulvestrant 40 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × margetuximab × Clear all

NCT02492711 2025-03-17

SOPHIA

MacroGenics

Phase 3 Completed

624 enrolled 17 charts 1 FDA

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡